Difficulty: Medium
Average Score: 94%
Practice
Recombinant human insulin in diabetes mellitus:
Correct answer
B
Rationale
Recombinant human insulin is the preferred choice in managing diabetes mellitus for several reasons. The correct answer, option B, states that the effective dose of recombinant human insulin may be less than animal insulin. This is because human insulin is structurally identical to the insulin produced by the human body, leading to a more precise and efficient response to glucose levels.
Option A, stating that recombinant human insulin never produces allergic reactions, is incorrect. While rare, allergic reactions can still occur with recombinant human insulin, just like with any medication.
Option C, suggesting that patients are less aware of hypoglycemia with recombinant human insulin, is also incorrect. In fact, patients should be equally vigilant for hypoglycemia regardless of the type of insulin they are using.
Option D, stating that recombinant human insulin should not be given intravenously, is incorrect as well. Recombinant human insulin can be given intravenously in certain clinical situations, such as in a hospital setting during diabetic ketoacidosis treatment.
In an educational context, it is important for healthcare providers to understand the differences between recombinant human insulin and animal insulin, as well as the appropriate use and administration of insulin therapy in diabetes management. Understanding these concepts can help optimize patient care and outcomes in individuals with diabetes.
Option A, stating that recombinant human insulin never produces allergic reactions, is incorrect. While rare, allergic reactions can still occur with recombinant human insulin, just like with any medication.
Option C, suggesting that patients are less aware of hypoglycemia with recombinant human insulin, is also incorrect. In fact, patients should be equally vigilant for hypoglycemia regardless of the type of insulin they are using.
Option D, stating that recombinant human insulin should not be given intravenously, is incorrect as well. Recombinant human insulin can be given intravenously in certain clinical situations, such as in a hospital setting during diabetic ketoacidosis treatment.
In an educational context, it is important for healthcare providers to understand the differences between recombinant human insulin and animal insulin, as well as the appropriate use and administration of insulin therapy in diabetes management. Understanding these concepts can help optimize patient care and outcomes in individuals with diabetes.